Correlation Between Syndax Pharmaceuticals and Larimar Therapeutics

Can any of the company-specific risk be diversified away by investing in both Syndax Pharmaceuticals and Larimar Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Syndax Pharmaceuticals and Larimar Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Syndax Pharmaceuticals and Larimar Therapeutics, you can compare the effects of market volatilities on Syndax Pharmaceuticals and Larimar Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Syndax Pharmaceuticals with a short position of Larimar Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Syndax Pharmaceuticals and Larimar Therapeutics.

Diversification Opportunities for Syndax Pharmaceuticals and Larimar Therapeutics

0.0

Correlation Coefficient

Syndax Pharmaceuticals  Larimar Therapeutics

Pay attention - limited upside

The 3 months correlation between Syndax and Larimar is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Syndax Pharmaceuticals and Larimar Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Larimar Therapeutics and Syndax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Syndax Pharmaceuticals are associated (or correlated) with Larimar Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Larimar Therapeutics has no effect on the direction of Syndax Pharmaceuticals i.e., Syndax Pharmaceuticals and Larimar Therapeutics go up and down completely randomly.

Pair Corralation between Syndax Pharmaceuticals and Larimar Therapeutics

Given the investment horizon of 90 days Syndax Pharmaceuticals is expected to generate 0.69 times more return on investment than Larimar Therapeutics. However, Syndax Pharmaceuticals is 1.45 times less risky than Larimar Therapeutics. It trades about 0.06 of its potential returns per unit of risk. Larimar Therapeutics is currently generating about -0.15 per unit of risk. If you would invest  1,252  in Syndax Pharmaceuticals on December 29, 2024 and sell it today you would earn a total of  104.00  from holding Syndax Pharmaceuticals or generate 8.31% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Syndax Pharmaceuticals  vs.  Larimar Therapeutics

Syndax Pharmaceuticals

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Syndax Pharmaceuticals are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain fundamental indicators, Syndax Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Larimar Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Larimar Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's primary indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Syndax Pharmaceuticals and Larimar Therapeutics

The main advantage of trading using opposite Syndax Pharmaceuticals and Larimar Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Syndax Pharmaceuticals position performs unexpectedly, Larimar Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Larimar Therapeutics will offset losses from the drop in Larimar Therapeutics' long position.

The idea behind Syndax Pharmaceuticals and Larimar Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.